TherapeuticsMD Inc (NASDAQ:TXMD) Director Tommy G. Thompson bought 5,000 shares of the firm’s stock in a transaction dated Wednesday, August 30th. The shares were acquired at an average price of $5.99 per share, with a total value of $29,950.00. Following the completion of the transaction, the director now owns 3,555 shares of the company’s stock, valued at approximately $21,294.45. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Shares of TherapeuticsMD Inc (NASDAQ:TXMD) traded down 0.83% during trading on Friday, hitting $5.95. The stock had a trading volume of 2,601,702 shares. TherapeuticsMD Inc has a 12 month low of $3.50 and a 12 month high of $8.30. The company’s 50 day moving average price is $5.70 and its 200 day moving average price is $5.55. The stock’s market cap is $1.21 billion.

TherapeuticsMD (NASDAQ:TXMD) last posted its earnings results on Thursday, August 3rd. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.11) by $0.01. TherapeuticsMD had a negative return on equity of 77.41% and a negative net margin of 462.94%. The firm had revenue of $4.25 million for the quarter, compared to analyst estimates of $4.91 million. During the same quarter in the prior year, the company earned ($0.11) EPS. TherapeuticsMD’s revenue was down 3.4% on a year-over-year basis. Equities research analysts expect that TherapeuticsMD Inc will post ($0.44) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was first posted by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://www.watchlistnews.com/tommy-g-thompson-purchases-5000-shares-of-therapeuticsmd-inc-txmd-stock/1536817.html.

Institutional investors have recently bought and sold shares of the company. Raymond James Financial Services Advisors Inc. raised its position in TherapeuticsMD by 56.1% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 28,730 shares of the company’s stock valued at $207,000 after buying an additional 10,330 shares during the last quarter. Greenwood Capital Associates LLC raised its position in TherapeuticsMD by 17.5% in the first quarter. Greenwood Capital Associates LLC now owns 20,309 shares of the company’s stock valued at $146,000 after buying an additional 3,022 shares during the last quarter. JPMorgan Chase & Co. raised its position in TherapeuticsMD by 2.5% in the first quarter. JPMorgan Chase & Co. now owns 13,725,853 shares of the company’s stock valued at $98,827,000 after buying an additional 329,245 shares during the last quarter. Stifel Financial Corp raised its position in TherapeuticsMD by 125.4% in the first quarter. Stifel Financial Corp now owns 429,362 shares of the company’s stock valued at $3,091,000 after buying an additional 238,885 shares during the last quarter. Finally, American International Group Inc. raised its position in TherapeuticsMD by 7.1% in the first quarter. American International Group Inc. now owns 92,415 shares of the company’s stock valued at $665,000 after buying an additional 6,103 shares during the last quarter.

TXMD has been the subject of several research analyst reports. Deutsche Bank AG initiated coverage on TherapeuticsMD in a research report on Friday, July 21st. They set a “buy” rating and a $10.00 target price for the company. Jefferies Group LLC set a $15.00 target price on TherapeuticsMD and gave the stock a “buy” rating in a research report on Wednesday, June 14th. Stifel Nicolaus reiterated a “buy” rating and set a $20.00 target price on shares of TherapeuticsMD in a research report on Wednesday, May 24th. Noble Financial reiterated a “buy” rating on shares of TherapeuticsMD in a research report on Friday, August 4th. Finally, Oppenheimer Holdings, Inc. set a $10.00 target price on TherapeuticsMD and gave the stock a “buy” rating in a research report on Thursday, August 17th. One research analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. TherapeuticsMD presently has an average rating of “Buy” and an average target price of $16.14.

About TherapeuticsMD

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Receive News & Ratings for TherapeuticsMD Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.